Dana-Farber Cancer Institute shared a post on LinkedIn:
“Our researchers have developed an experimental AI-based oncologist’s assistant to study how large-language models could support precision oncology decision-making.
With more than 100 precision cancer medicines approved – and approvals advancing rapidly – staying current is increasingly complex. In early testing, the tool showed promising accuracy.
“We wanted to see if we could create an assistant that can be helpful to an oncologist without taking away the autonomy, decision making, and relationship between the patient and provider, and we’ve learned both that it is possible and that there is more work to be done,” says Eliezer Van Allen, MD, chief of the Division of Population Sciences.
The assistant is intended for research purposes, with additional study needed before clinical use. Learn more.”
